BridgeMD
Tests treatment safety and results for Pheochromocytoma
Official title The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma
ClinicalTrials.gov ID: NCT05702944
What this study is testing
What is Phenoxybenzamine?
Phenoxybenzamine is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for pheochromocytoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors originating from catecholamine producing chromaffin cells in the adrenal medulla and extra-adrenal paraganglia. The overall age-standardized incidence rate is 0.18 per 100,000 person-years in Korea.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 to 70
You may be able to join if
- Patients aged 19 to 70 years old
- Patients who consented to the study and obtained consent for the study
- Patients undergoing unilateral total adrenalectomy due to normotensive pheochromocytoma/paraganglioma with less than five times of upper limits of...
You likely can't join if
- Patients under 18 or over 70 years old
- Pregnant women
- Patients with bilateral pheochromocytoma
- Patients suspected of malignant pheochromocytoma/paraganglioma or distant metastasis
- Patients requiring preoperative intensive care unit due to severe hemodynamic instability
- Patients with hypertension (the blood pressure measured more than two times is constantly greater than 140/90 mmHg) or already taking a...
See the full eligibility criteria
- Patients aged 19 to 70 years old
- Patients who consented to the study and obtained consent for the study
- Patients undergoing unilateral total adrenalectomy due to normotensive pheochromocytoma/paraganglioma with less than five times of upper limits of serum metanephrine
- Patients under 18 or over 70 years old
- Pregnant women
- Patients with bilateral pheochromocytoma
- Patients suspected of malignant pheochromocytoma/paraganglioma or distant metastasis
- Patients requiring preoperative intensive care unit due to severe hemodynamic instability
- Patients with hypertension (the blood pressure measured more than two times is constantly greater than 140/90 mmHg) or already taking a antihypertensive medication
- Patients with a history of coronary artery disease
- Patients with a history of arrhythmia (atrial fibrillation, Paroxysmal supraventricular tachycardia)
- Patients with a history of cerebrovascular disease (cerebral aneurysm, cerebral infarction, cerebral hemorrhage)
- Patients judged unsuitable by the person in charge of the clinical trial
The study team makes the final eligibility decision.
Where it's taking place
- Seoul, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seoul, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.